单克隆Anti FMC63抗体-ACROBiosystems百普赛斯

PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation) (Preservative free)

抗体来源（Source）

PE标记的单克隆抗FMC63抗体小鼠IgG1（FM3-HPY53）是通过PE与单克隆抗FMC63抗体小鼠IgG1在最佳条件下通过专有技术进行位点特异性缀合而产生的。我们还携带另一种含proclin的PE标记单克隆抗FMC63抗体，小鼠IgG1（FM3-PY54A2），除proclin外，其他生产工艺相同，含proclin的产品具有相同的性能，重组后可在2-8°C下保存不少于12个月。

此外，我们携带另一种premium级别PE标记的单克隆抗FMC63抗体，小鼠IgG1（Y45）（FM3-PY54G0），采用相同的生产工艺生产，但采用更严格的质量控制系统，该系统包括一系列全面的测试，包括无菌和内毒素测试。它专为临床前早期的细胞分离和细胞培养应用而设计。

应用（Application）

Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression). Please note that this product is NOT compatible to streptavidin detection system.

克隆号（Clone）

Y45

种属（Species）

Mouse

亚型（Isotype）

Mouse IgG1/kappa

特异性（Specificity）

Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

免疫原（Immunogen）

Recombinant FMC63 scFv derived from HEK293 cells.

偶联（Conjugate）

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

同型对照（Isotype Control）

The Isotype control is sold separately and you can search for Cat. No. DNP-PM1 for product information.

推荐稀释比（Recommended Dilution）

1:50

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 12 months under sterile conditions after reconstitution.

背景（Background）

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.